Patents by Inventor Christoph Schliemann

Christoph Schliemann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY COMPRISING AN INFLAMMATORY IMMUNOCYTOKINE AND A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL
    Publication number: 20190125840
    Abstract: The present invention relates to a combination comprising at least fusion protein comprising a binding protein specifically recognizing a cancer-related antigen and an inflammatory cytokine, and a chimeric antigen receptor (CAR)-T cell recognizing a cancer-related antigen.
    Type: Application
    Filed: April 12, 2017
    Publication date: May 2, 2019
    Inventors: Wolfgang Berdel, Claudia Rossig, Christoph Schliemann, Bianca Altvater, Sareetha Kailayangiri
  • Targeting of bone marrow neovasculature
    Patent number: 9446124
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukemia patients, for use in treatment and diagnosis of leukemia, in particular the treatment and diagnosis of acute myeloid leukemia (AML).
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: September 20, 2016
    Assignee: Philochem AG
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
    Patent number: 9289470
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 22, 2016
    Assignee: PHILOGEN S.P.A.
    Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART
    Publication number: 20140294723
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: June 17, 2014
    Publication date: October 2, 2014
    Applicant: PHILOGEN S.P.A.
    Inventors: Dario Neri, Hans Menssen, Andreas Menrad, Christoph Schliemann
  • Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
    Patent number: 8796426
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: August 5, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • Targeting of Bone Marrow Neovasculature
    Publication number: 20140199238
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
    Type: Application
    Filed: March 19, 2014
    Publication date: July 17, 2014
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Targeting of bone marrow neovasculature
    Patent number: 8679488
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: March 25, 2014
    Assignee: Philogen S.p.A.
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Targeting of Bone Marrow Neovasculature
    Publication number: 20120121506
    Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).
    Type: Application
    Filed: August 2, 2010
    Publication date: May 17, 2012
    Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
  • Cancer Treatment
    Publication number: 20110318302
    Abstract: The invention relates to the treatment of cancer, e.g. kidney cancer, using chemotherapeutic agents and immunocytokines, in particular immunocytokines which bind to the Extra Domain-A (ED-A) isoform of fibronectin.
    Type: Application
    Filed: December 23, 2009
    Publication date: December 29, 2011
    Inventors: Kathrin Schwager, Katharina Frey, Christoph Schliemann, Neri Dario
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND /OR THEIR CANCEROUS COUNTERPART
    Publication number: 20100310454
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: November 8, 2008
    Publication date: December 9, 2010
    Inventors: Dario Neri, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann
  • COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART
    Publication number: 20090202473
    Abstract: The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
    Type: Application
    Filed: November 13, 2008
    Publication date: August 13, 2009
    Inventors: Dario NERI, Hans Dietrich Menssen, Andreas Menrad, Christoph Schliemann